Biocon is engaged in the business of manufacture of biotechnology products and research
Key Point:- Products
Biologics (31% of sales)
Has one of the largest biosimilar pipelines comprising 28 molecules to be launched over
the next decade. Only Indian company to get FDA approval for 3 biosimilar molecules
(Trastuzumab, Pegfilgrastim and Insulin Glargine).Aspires to reach $1bn revenues by
FY22.Biologics division has been valued at $4.17bn as per the last fund raising
round.Biocon plans to list this division separately.
Syngene, the research services arm of biocon, was listed as an independent company in
2015.Syngene is an integrated CDMO offering research, development and manufacturing
services for small and large molecules, antibody-drug conjugates and oligonucleotides.
Technical View: Biocon, In long run it is on uptrend and recently had an ascending triangle
breakout with strong Bullish candle on daily chart.Last session chart have formed Bearish candle
on daily chart due to consolidation.Overall structure and trend indicate positive trend, RSI
divergence indicate buy signal and MACD crossover supporting trend.
Volume analysis: – 1 Day Delivery volume increased by 8.24% over 5 day average, However; 1
Month: Delivery volume Increase by 31.84%, Hence; We recommend BUY signal for this share at
the range of 390 for Target 410 , Target 440, Target 475 Use Strict stop loss 370.
Moving Averages: – Biocon Ltd. is trading higher than 5 day, 20 day, 50 day, 100 day and 200
day moving averages .
5 Day 370.80 50 Day 364.73 200 Day 372.86
20 Day 365.37 100 Day 359.69
Promoters holding 60 %, No change in Promoter holdings, No change in Promoter pledged